Vasolax Tablet (Controlled Release) CR Tablet 400 mg is a Product of the Generic Pentoxifylline

What Is Vasolax Tablet (Controlled Release) CR Tablet 400 mg Indications and Uses?

This is indicated in- Peripheral arterial occlusive disease (PAOD) of arteriosclerotic or diabetic origin (e.g. with intermittent claudication and rest pain) Trophic lesions (e.g. leg ulcers and gangrene) Cerebral vascular diseases Circulatory disturbances of the eye in conjunction with degenerative vascular disorders.

Pharmacology (Source, Chemical and Physical Composition) Of Vasolax Tablet (Controlled Release) CR Tablet 400 mg

Vasolax Tablet (Controlled Release) CR Tablet 400 mg (Pentoxifylline) and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise mode of action of pentoxifylline and the sequence of events leading to clinical improvement are still to be defined. Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility. Leukocyte properties of hemorrheologic importance have been modified in animal and in vitro human studies. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation. Tissue oxygen levels have been shown to be significantly increased by therapeutic doses of pentoxifylline in patients with peripheral arterial disease.

Dosage And Administration of Vasolax Tablet (Controlled Release) CR Tablet 400 mg

In principle, dosage is based on the type and severity of the circulatory disorders and on how the individual patient tolerates the drug. Usual dosage is 400 mg Vasolax Tablet (Controlled Release) CR Tablet 400 mg (Pentoxifylline) 2 to 3 times daily. Tablets are to be swallowed whole during or shortly after a meal with sufficient amounts of liquid (approx. ½ glass).

Drug Interactions of Vasolax Tablet (Controlled Release) CR Tablet 400 mg

Precautions for use: The blood-sugar-lowering effect of insulin or oral antidiabetics may be potentiated. Therefore it is recommended that patients under medication for diabetes mellitus be carefully monitored. Post-marketing cases of increased anti-coagulant activity have been reported in patients concomitantly treated with Vasolax and anti-vitamin K. Monitoring of anti-coagulant activity in these patients is recommended when Vasolax is introduced or the dose is changed. Take into account: The blood-pressure-lowering efect of antihypertensive agents and other drugs with blood-pressure-lowering potential may be increased by Vasolax. Concomitant administration of Vasolax and theophylline may increase theophylline levels in some patients. Therefore, there may be an increase in and intensifcation of adverse reactions from theophylline. Concomitant administration with ciprofoxacin may increase the serum concentration of Vasolax in some patients. Therefore, there may be an increase in and intensifcation of adverse reactions associated with co-administration. Potential additive efect with platelet aggregation inhibitors: Because of the increased risk of bleeding, the concomitant administration of a platelet aggregation inhibitor (such as clopidogrel, eptifibatide, tirofiban, epoprostenol, iloprost, abciximab, anagrelide, NSAIDs other than selective COX-2 inhibitors, acetylsalicylates [ASA/LAS], ticlopidine, dipyridamole) with Vasolax should be undertaken with caution. Concomitant administration with cimetidine may increase the plasma concentration of Vasolax and the active Metabolite.

Side Effects of Vasolax Tablet (Controlled Release) CR Tablet 400 mg

These adverse reactions have been reported in clinical trials or post-marketing- Investigations: Transaminases increased (Transaminase elevation), Blood pressure decreased (Fall in blood pressure) Cardiac disorders: Arrhythmia (Cardiac arrhythmia), Tachycardia, Angina Pectoris Blood and lymphatic system disorders: Thrombocytopenia (Thrombopenia), Leucopenia/neutropenia Nervous system disorders: Dizziness, headache, meningitis aseptic (Aseptic meningitis) Gastrointestinal disorders: Gastrointestinal disorder (Gastrointestinal complaints), Epigastric discomfort (Gastric pressure), Abdominal distension (Fullness), Nausea, Vomiting, Diarrhoea, Constipation, Hypersalivation Skin and subcutaneous tissue disorders: Pruritus, Erythema (Reddening of the skin), Urticaria, Rash Vascular disorders: Hot fush (Flushes), Haemorrhage (Bleedings) Immune system disorders: Anaphylactic reaction, Anaphylactoid reaction, Angioedema (Angioneurotic edema), Bronchospasm, Anaphylactic shock (shock) Hepatobiliary disorders: Cholestasis (Intrahepatic cholestasis) Psychiatric disorders: Agitation, Sleep disorder (Sleep disturbances)

Precautions And Warnings for Vasolax Tablet (Controlled Release) CR Tablet 400 mg

At the first signs of an anaphylactic/anaphylactoid reaction, Vasolax must be discontinued or the infusion be halted immediately, and a physician must be informed. Particularly careful monitoring is required: in patients with severe cardiac arrhythmias in patients with myocardial infarction in hypotensive patients in patients with impaired renal function (creatinine clearance below 30 ml/min) in patients with severely impaired liver function in patients with increased bleeding in patients treated concomitantly with Vasolax and anti-vitamin K or platelet aggregation inhibitors in patients treated concomitantly with Vasolax and antidiabetic agents in patients treated concomitantly with Vasolax and ciprofoxacin in patients treated concomitantly with Vasolax and theophylline

Use During Pregnancy and Lactation

Insufficient experience has been gained concerning use in pregnancy. Therefore, it is recommended that Vasolax Tablet (Controlled Release) CR Tablet 400 mg (Pentoxifylline) is not used during pregnancy. Pentoxifylline passes into breast milk in minute quantities. Because insufficient experience has been gained, the physician must carefully weigh the possible risks and benefits before administering Pentoxifylline in breast-feeding women.

Therapeutic Class

Peripheral Vasodilator drugs: Intermittent Claudication

Storage Conditions of It

Keep in a cool and dry place, away from light. Do not use later than date of expiry. Keep all medicine out of the reach of children. To be dispensed only on the prescription of a registered physician. Thanks for using MedEx! How would you rate your experience so far?